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Abstract 
Phase II oncology trials are carried out to assess whether an experimental anti-cancer 
treatment shows sufficient signs of effectiveness to justify being tested in a phase III trial. 
Traditionally such trials are conducted as single arm studies using a binary response rate as 
the primary endpoint. In this article we review and contrast alternative approaches for such 
studies. Each approach uses only data that are necessary for the traditional analysis. We 
consider two broad classes of methods: ones that aim to improve the efficiency using novel 
design ideas, such as multi-stage and multi-arm multi-stage designs; and ones that aim to 
improve the analysis, by making better use of the richness of the data that is ignored in the 
traditional analysis.  The former class of methods provides considerable gains in efficiency, 
but also increases the administrative and logistical issues in running the trial. The second 
class consists of viable alternatives to the standard analysis that come with little additional 
requirements and provide considerable gains in efficiency.  









Phase II oncology trials are carried out to assess whether an experimental anti-cancer 
treatment shows sufficient signs of effectiveness to justify being tested in a phase III trial. 
Currently the success rate of phase III oncology trials is found to be unacceptably low (1;2) 
and a major reason is due to inadequate early phase trials. 
In most tumour types, the gold-standard endpoint of time-to-death (which is often used in 
phase III trials) is not feasible for use in phase II trials. This is due to substantial progress in 
increasing survival rates for most tumour types, meaning the time taken to observe time-to-
death is too long. Instead, endpoints that are relatively quickly observed and that are thought 
to be informative for time-to-death are used. It is clear that, whichever endpoint is used 
instead of the gold-standard endpoint of time-to-death, needs to be clinically relevant and the 
collected information needs to be expected to provide a reliable assessment of whether or not 
to proceed to phase III. For solid-tumours, the focus of this paper, the first attempt to 
standardise the assessment of anticancer agents was the World Health Organisation (WHO) 
criteria (3). The WHO criteria categorised the change in number and size of measurable 
tumour lesions. As technology for scanning tumour lesions advanced, several modifications 
to the WHO criteria were introduced. This led to different organisations using inconsistent 
evaluations of anti-tumour effect. The RECIST criteria, originally proposed in 2000 (4) and 
updated in 2009 (5), was an attempt to provide a consistent mechanism for evaluating anti-
cancer treatments. RECIST categorises the change in the size and number of tumour lesions 
into four levels: complete response (CR), partial response (PR), stable disease (SD) and 
progressive disease (PD) to which death is frequently added as a further category.  RECIST 
has had a wide uptake and currently endpoints that use RECIST categories are used in the 
vast majority of solid-tumour Phase II trials.  
Endpoints based on RECIST that are regularly used in early oncology trials are: 1) the 
response rate (RR), which is a binary outcome with the treatment classed as successful if the 
patient experiences a CR or PR and as a failure otherwise; 2) the disease control rate (DCR), 
which modifies RR to include SD as a success; 3) progression-free-survival (PFS), which is 
the time until a patient experiences PD or is dead. RR and DCR can be further divided into 
best observed response and response at a fixed time. For best observed response, patients are 
assessed at regular intervals until they progress, and the best observed RECIST outcome 
before progression is classified as a success or failure using RR or DCR. The fixed time 
analysis assesses RR or DCR at a fixed time after randomisation, for example after the 
treatment finishes. 
Many statistical methods have been proposed for improving early oncology trials. These 
improvements may be to increase the power of the trial, to improve the efficiency of the trial 
(i.e. reduce the number of patients required on average), or to improve the ability of the trial 
to predict whether the treatment will be successful at phase III. In this paper we aim to 
provide a review of some important proposed methods, and to provide recommendations 
about their use. While our focus of this paper is Phase II studies, many aspects discussed here 
overlap with pilot studies, which have been defined as a “small study for helping to design a 
further confirmatory study” (6), and hence some of the methods will also be applicable to 
them. 
2. A standard design and its multi-stage extension 
A standard trial design for early cancer studies is to use a single arm design with response 
rate as the primary endpoint. This design tests 
H0: p = p0  vs  H1: p > p0    (1) 
where p is the response rate on the treatment under investigation and p0 is a fixed constant 
that represents the response rate on the standard treatment or standard of care. The value of p0 
may be chosen from clinical judgement or from historical control data. Generally a total 
number of n patients would be recruited so that the power of the trial to reject H0 is equal to 
1-β when the true response rate on the experimental treatment is p=p1 with p1 being a 
response rate that  indicates the treatment is promising and warrants further trials. The null 
hypothesis is rejected in favour of the alternative if the total number of successes exceeds a 
critical value r which is chosen to give a one-sided significance level of α. The sample size 
and critical value are typically determined either by employing a normal approximation or 
using exact binomial probabilities (see e.g. Machin (7)). 
A frequently used modification of this standard design is to utilize (group-) sequential 
methods that allow interim analyses to be carried out after groups of patients have been 
assessed.  Often, a two-stage design is used for early cancer studies which, as its name 
implies, splits the trial into two stages. In the first stage a total of n1 patients are recruited and 
assessed. If the number of responders in the first stage is below a pre-specified value, f, the 
trial stops for futility, and H0 is not rejected. If the number of responders exceeds an upper 
bound, e1, the trial stops for efficacy and H0 is rejected. If the trial continues to the second 
stage, n2 additional patients are recruited and assessed. At the end of the second stage, H0 is 
rejected if the total number of responders is above a threshold e2.  
The advantage of a two-stage design is that the expected sample size (ESS) is often lower 
than n, the number of patients required in the one-stage design. This is good for the average 
cost and length of the trial and also is more ethical as a truly ineffective drug will be given to 
fewer patients, on average. However a drawback is that the maximum sample size (MSS), 
equal to n1+n2, is generally larger than n would be for a single stage design with the same 
type I error rate and power. That is, if the two-stage trial continues to a second stage, the 
sample size used will usually be greater than would have required for a trial without an 
interim analysis. We should note that ESS (but not MSS) depends on the true response rate, 
p. Although it is not necessary to allow both stopping for futility and efficacy in the first 
stage, doing so provides a broader range of values of p that result in ESS being lower than n. 
Simon (8) proposed two different two-stage designs that allow early stopping for futility at an 
interim analysis. The first, called the optimal design, is the two-stage design with required 
type I error rate and power that minimises the ESS when p=p0. The second, called the 
minimax design, minimises the maximum sample size (MSS) i.e. (n1+n2). Since MSS is an 
integer value, several designs will have this property: the minimax design is the one amongst 
these with the lowest ESS when p=p0. Both the optimal and minimax designs have ESS 
values that are considerably lower than the sample size that would be required for a one-stage 
design without interim analyses.  
Simon’s two-stage design has been used frequently in practice (9;10) and the original paper 
cited over 2000 times. It has also been extended in many ways. Firstly, the original design 
only allows stopping for futility, effectively setting the value of e1 to n1. Schuster (11) and 
Mander and Thompson (12) consider optimal designs that allow early stopping for efficacy. 
In the case of early stopping for futility and efficacy, the ESS generally starts low for very 
low values of p (as early stopping for futility is likely), increases to a maximum, and then 
decreases again for large values of p (where early stopping for efficacy is likely). Mander and 
Thompson consider the design that has the lowest ESS when p=p1, and Shuster considers the 
design that minimises the maximum ESS (i.e. the peak of the ESS curve). Designs that allow 
early stopping for efficacy will increase the efficiency of the trial considerably when the drug 
is truly effective. They also have the drawback that estimates of the success probability for a 
successful treatment will be based on fewer patients, which may be undesirable for the 
planning of a new trial. 
A second useful modification is generalising optimal designs to consider more than one 
optimality criteria. Designs that optimise a single criterion often perform poorly on other 
criteria that might be of interest. For example, Simon’s optimal design typically has a large 
MSS. Jung et al. (13) propose using admissible designs. For a specified set of optimality 
criteria (Jung et al. consider the ESS under 
0
p p  and the MSS), an admissible design is one 
which is optimal for a weighted sum of the two criteria. That is, it minimises: 
 
0
( ) MSS(1 ,)ESS p p     (2) 
for some value of        . There will in general be a finite set of admissible designs, all of 
which balance the criteria in different ways. An interesting observation made by Jung et al. is 
that an admissible design for   close to 1 will have an ESS close to the ESS of the optimal 
design, but a notably lower MSS than the optimal design. Admissible designs can be applied 
with more than two criteria - designs that consider the ESS at p=p0,  the ESS at p=p1 and the 
MSS were considered by Mander et al. (14). Admissible designs can also consider criteria 
other than sample sizes – for example, Bowden and Wason (15) considered the expected 
sample size and subsequent estimation performance, in terms of bias and mean squared-error, 
following a two-stage design. 
A third modification is to consider more than two-stages. Ensign et al. (16) and Chen (17) 
considered extending Simon’s optimal design to three stages. Chen and Shan (18) considered 
optimal and minimax three-stage designs that also allow early stopping for efficacy. 
Generally adding stages in a multi-stage design provides diminishing returns - going from a 
two-stage design to a three-stage design  reduces the ESS by a small amount compared to the 
reduction from going from a one-stage to a two-stage.  
Although Simon’s original paper (8) considered a single-arm trial with a binary endpoint, 
group-sequential design theory (for a broad and thorough overview, see Jennison and 
Turnbull (19)) can more generally be applied to two-arm trials comparing an experimental 
arm to a control arm. It can also be applied to a wide variety of endpoints, including normally 
distributed and time-to-event. Normally distributed endpoints are rare in early oncology trials 
(with the exception of considering the change in tumour size directly, which we consider 
further in section 3); time-to-event endpoints are common however, with progression-free 
survival and time-to-progression two frequently used endpoints in randomised phase II trials. 
In this case, multi-stage designs can still be applied to improve efficiency – Schaid et al. (20) 
describe the required methodology when the log-rank test is used as the test statistic. Other 
modifications described above are also more generally applicable, with minor modifications, 
to randomised phase II trials (for example, see (21) for use of admissible designs in a 
randomised two-arm setting) and other primary endpoints, such as progression-free survival, 
as well.   
Recent methodological work has focused on development of multi-arm multi-stage (MAMS) 
designs. These allow more than one experimental arm to be compared against a common 
control arm. At interim analyses, experimental arms can be dropped for futility if they have 
performed poorly (22-24) . Efficacy stopping can also be allowed if it is of interest tofind 
only a single effective experimental treatment. For a recent review on different classes of 
MAMS designs, and how they might be useful in phase II trials, see Wason (25) while (26) 
provides some general recommendations on these designs. 
3. Alternative endpoints 
3.1 Using a categorical endpoint 
Using a binary endpoint for early phase cancer trials has become an established standard, yet 
it is well known that dichotomizing a categorical variable leads to a loss of information and is 
hence inefficient (27;28). As a consequence a natural alternative is to utilize the categorical 
information directly in the design of the early oncology studies. Such a trial could consider 
the log-odds ratio, defined as  
      (
          
          
) 
where Qjk = pj1 +…+ pjk and pjk is the is the probability that a patient on treatment j has an 
outcome in category Ck. It is clear from the definition of the parameter of interest, however, 
that both information on the experimental treatment and a comparator, indexed by zero here, 
is required. As a consequence response values for the comparator would need to be specified 
and assumed for single arm studies frequently utilized in early cancer studies which may be 
difficult to achieve. For comparative studies, however, such an approach will be efficient and 
details on how to obtain sample sizes have been studied (29) and extended to multiple 
experimental treatments (30). In either case the solution is based on efficient score statistics 
and hence approximate and proportional odds (27) are assumed. For the two-arm comparative 
setting, the critical value, c, and the corresponding sample size have been derived as  
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for a trial randomizing in an R:1 ratio in favour of control. In equation (2), θ represents the 
clinically relevant effect and  ̅  is the average proportion across arms in response category i.  
3.2. Using tumour size 
Another natural alternative to using binary response based on RECIST is based on the 
recognition that the RECIST categories are largely based on the change in the size of the 
lesions. In their simplest form (31;32) the change in (possibly transformed) tumour size is 
modelled as being normally distributed allowing standard methods to be used. This brings the 
advantage that the continuous variable underlying the RECIST categories is utilized directly 
and hence the well known loss in efficiency resulting from categorizing a continuous variable 
(33)  is avoided.  A short-coming of using tumour size directly is that other relevant 
information used in RECIST, such as death or new lesions, are not used. Two different 
approaches have been proposed to overcome this issue. 
The first, by Karrison et al. (32), uses the continuous tumour shrinkage (on the log tumour 
ratio scale) as a primary endpoint. It is suggested that patients who die or progress due to new 
lesions are included in the analysis, but their outcome is set to the worst observed log tumour 
size ratio amongst other patients. Similarly, as complete responses have an undefined log 
tumour ratio, their outcome is set to the best observed outcome amongst other patients. As 
this procedure is likely to cause deviations from normality, it is recommended that a non-
parametric test is used. 
Jaki et al. (34) propose to overcome this issue by combining two separate test statistics that 
can be related to the same endpoint and describe their solution for a comparative study. In 
particular they construct the design based on survival to the end of the study and a continuous 
tumour size measurement for all patients that are alive at the end of follow-up. Jaki et al. 
suggests that one begins by considering the binary variable that captures whether a patient 
has survived until the tumour size measurement post treatment is scheduled (often several 
months after initiation of the treatment). Using a generalized linear model the treatment 
effect,   , on the binary survival variable for patients who died can be straightforwardly 
estimated. Similarly, the treatment effect on the change in tumour size,     , can be estimated 
using a linear model based on all patients that have survived long enough, provided that the 
endpoint is (approximately) normally distributed. Note that this construction allows for a 
natural way to include covariates in the analysis. Using a score statistic framework, the 
corresponding estimators will be approximately normal with the mean corresponding to the 
underlying parameter times the information level and variance equal to the information level 
so that standard tests for each of the parameters separately can be constructed. 
To avoid having to consider two separate hypothesis tests that may contradict each other, Jaki 
et al. proceed by combining the two test statistics into a single statistic testing one parameter 
namely the log-hazard ratio for overall survival,    . To do so they recognize, that the binary 
survival parameter in the generalized linear model is exactly as the log-hazard ratio provided 
that a complementary log-log link is used (35). Additionally this relationship is still 
approximately true if a logit link is used. To derive a similar relationship between overall 
survival and change in tumour size, they use a historical dataset on the control treatment to 
estimate this relationship using a Cox proportional hazards model. 
Using these ingredients, the distributions of the score statistics, denoted by S, can be written 
as  
               and         (
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where Vs and VCTS are the Fisher information for the binary survival and change in tumour 
size, respectively, and      is the coefficient of the Cox proportional hazards model 
associated with change in tumour size. Combining the two test statistics as    
 
     
     
then allows construction of a single test for whether the log hazard ratio is 0 (i.e. whether 
there is a treatment effect on overall survival) based on change in tumour size information. 
To design the study, standard results for score statistics can be used to find the critical value, 
u, and the sample size as  
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were     is the interesting treatment effect in terms of overall survival,  
  the variance of the 
change in tumour size measurements,   ̅, is the average proportion of patients dying before 
the post treatment tumour size measurement can be taken and           ̅ . 
The original publication discusses using a binary endpoint capturing survival until a post-
treatment measurement of the tumour size can be obtained. It is, however, straightforward to 
use other measures used in RECIST besides survival as well. For example the binary variable 
could capture if additional lesions have developed. 
3.3. Improving analyses of existing endpoints 
Despite many alternative endpoints existing that provide potential benefits over traditional 
early phase endpoints based on RECIST, they have only been used in a limited number of 
trials. For better or for worse, RR, DCR, TTP and PFS have gained widespread acceptability 
with clinicians conducting trials. Instead of attempting to shift practice, an alternative strategy 
is to attempt to improve analyses that use existing endpoints. 
With this in mind, Wason and Seaman (36) proposed the augmented binary method. This 
assumes the endpoint of interest is a binary outcome, such as RR or DCR, which is measured 
at a fixed time (in terms of number of assessments rather than calendar time). In this case, a 
treatment is successful for a patient if the tumour shrinkage is above a certain threshold, and 
there is no treatment failure for other reasons (such as new lesions).  
Tumour size measurements are assumed to be taken at baseline, some intermediate time, and 




zz z . Indicators 
for whether failure occurred for a reason other than unacceptable tumour growth (henceforth 
called non-growth failures) are denoted as:
1i
D  = 1 if patient i has a non-growth failure before 
the interim measurement, and 
2 i
D  = 1 if patient i has a non-growth failure between the 
interim measurement and the end of treatment. Typically, the log tumour-size ratio: 
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is used due to it being well approximated by the normal distribution (31).  
 
The y and D variables determine the composite outcome. Si denotes the composite success 
indicator for patient i. If RR is used, then Si is equal to 1 if Di1=0, D2i=0 and y2i < log(0.7). 
That is, it is 1 if patient i has a tumour shrinkage of more than 30% at the end of treatment 
(which is the minimum requirement for PR in RECIST) and no non-shrinkage failure. It is 
missing if the patient drops out of the trial for a reason other than one of the failure criteria. 
More generally, a different threshold can be used if an endpoint other than RR is used. 
 
To estimate the probability of success, i.e. ( 1)
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Additional covariates can also be included in the tumour-shrinkage. For D, two separate 
logistic regressions are used: 
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Models  (2) and (2) can be combined to give the probability of success for patient i, with 
baseline tumour size 
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f y y  is the pdf of the bivariate normal distribution from equation (2). 
 
By repeating this for all patients in the dataset, an estimate of the overall probability of 
success is reached. To get a measure of uncertainty for the estimated probability of success 
the delta method is applied. For each arm in the trial, an estimated probability of success and 
associated 95% CI is found. For a single-arm trial, this CI can be compared against the null 
probability of success that was pre-specified; for a two-arm trial, the difference in success 
probably and 95% CI for the difference can be straightforwardly found. 
 
The augmented binary method can improve the precision of the estimated success probability 
considerably. The mean width of the CI using the method is equivalent to the mean width of 
the CI from the traditional approach with a 35% higher sample size. The efficiency gain does 
depend on the dichotomisation threshold used – if the number of treatment successes or 
failures in the trial is very low then the method does not do well. So if few partial or complete 
responses were to be expected, then one should use the augmented binary method on the 
DCR endpoint instead of the RR endpoint. 
The main current limitation of the augmented binary method is that it can only be applied to 
endpoints measured at a fixed timepoint. Thus it cannot be used on analyses using best 
observed response or PFS. It should be possible to extend the method to work on these 
endpoints, and this is an active area of research. A second limitation is that there are currently 
no analytical formulae for the sample size required for a trial using the augmented binary 
method. Wason and Seaman (36) suggested that the sample size calculation should assume 
the traditional analysis is to be used, and then the augmented binary method used to gain 
power. A simulation-based approach could alternatively be used if a specified power is 
required. 
4. Comparison of methods 
A variety of alternative designs have been proposed to improve Phase II cancer trials. From 
our description above it is clear that different approaches have advantages and disadvantages. 
In the conclusion of this work we provide comparisons of the different ideas under a broad 
range of criteria. A summary comparison of different designs is provided in Table 1 and some 
more details provided below.  
Uptake of methods 
Despite the availability of numerous alternative approaches, single arm trials based on a 
binary endpoint are by a large margin the most common. Whenever comparative trials are 
used they also tend to be based on binary response or PFS. There is some suggestion that 
evaluation of newer treatments, such as cytostatic agents, use comparative studies more 
frequently. Approaches using change in tumour size have been discussed for some time but 
their uptake to date is still limited while the augmented method, being a recent development, 
has not been applied to our knowledge. 
Simplicity 
In terms of simplicity two different aspects need to be considered. Is the approach intuitive 
and easy to explain to a non-statistician and how difficult is the method in terms of the 
underlying statistics. Once again the traditional approaches based on binary response fare 
well on both accounts. The underlying statistical ideas are standard and clinical experts are 
happy to embrace a design based on such an endpoint – possibly helped by the fact that this 
design has been used for many years. Similarly simple to explain to non-experts are designs 
based on continuous change in tumour size. This is helped by the wide use of RECIST and 
the familiarity with its derivation and experience with continuous data by many scientists. 
Using just the size of the tumour as in (32) is also straightforward statistically as standard 
methods for continuous data can be used. Once one allows for patients possibly not surviving 
long enough in order to obtain a tumour size measurement the statistical complexity increases 
drastically.  
The augmented approach in (36) is somewhat more complex to explain to non-experts as the 
underlying method is fairly statistically advanced. The design based on a categorical response 
mainly suffers from the difficulty to explain the proportional odds assumption to non-experts. 
The statistics underneath the approach is, however, relatively straightforward and should not 
pose any challenge to implement. 
Efficiency 
One of the most important considerations in any statistical design is to make best use of the 
available data. In the context of designing early oncology study we consider the number of 
subjects required to attain a particular power. It is clear, that single-arm studies have an unfair 
advantage over two-arm trials as no data on the control group is collected. Yet, Jaki et al. (34) 
show convincingly that their approach for a comparative trial based on continuous tumour 
size yields comparable sample sizes to a single arm trial based on a binary response. This can 
be explained by the well known fact that dichotomizing a continuous variable leads to a 
substantial loss on efficiency. Consequently the popular approach based on binary response is 
less efficient that using a categorical variable which is again less efficient than using a 
continuous response. The augmented binary method certainly improves efficiency over the 
binary analysis and has been shown to outperform Karrison’s continuous method (32)  in 
some, but not all, instances (36). A more detailed comparison against the more complex 
continuous method is yet to be undertaken, however. 
Single arm, two-armed and beyond 
All of the methods discussed in this work are applicable to two-arm comparisons. The 
continuous approach discussed in (34), however has not been developed for single arm 
studies. Similarly the design using categorical outcomes has not been developed except a 
simplified version that allows for partial and complete responses to be considered separately 
(37). For the approaches currently proposed for comparative trials, some modifications to the 
methods could be used to allow for single armed versions. As these would require some 
additional assumptions (e.g. proportions in each category for the control arm) that would be 
difficult to obtain, these approaches are unlikely to be useful for single arm studies in 
practice.  
Going beyond two arms, methods have been developed for multi-arm trials for binary 
responses (38;39), ordinal response (30;40) and simple continuous data (22;23). The more 
complex continuous method and the augmented approach have not been extended to this 
setting as of yet.   
Additional assumptions and information 
Underlying to all the discussed approaches is the desire to use information that is required in 
order to obtain the RECIST criteria. Despite that fundamental commonality the different 
approaches differ in the assumptions or information they require. It is, for example, clear that 
the RECIST categories themselves plus information on survival is sufficient to design a trial 
using a categorical endpoint. Similarly the simplification used by a binary response variable 
to group categories also does not require any additional data. In order to use a continuous 
change in tumour size endpoint and the augmented binary approach, however, the raw data 
on the size of the tumours will be required. In general this will not pose a particular challenge 
as these data are necessary in order to obtain the RECIST classification. For the method of 
Jaki et al. (34), however, a historical dataset on the control treatment which includes the raw 
tumour size measurements will be necessary in addition in order to relate the survival 
endpoint to the change in tumour size endpoint.  
Although not requiring any additional data, the categorical analysis and the augmented 
approach do make some additional assumptions. For categorical responses, the proportional 
odds assumption (27)  is typically made while an assumption about missing at random (MAR 
– see for example, (41)) is used for the augmented binary method. In both cases sensitivity 
analyses have shown that the methods are not highly sensitive to the respective assumptions, 
yet it is clear that some thought about the appropriateness of them is necessary.  
Interim analyses 
Finally, we have not discussed the utility of multi-stage designs any further nor included 
them in our comparison table. This is because using interim analysis is, in principle, possible 
for all different endpoints discussed. Our view is that allowing for early stopping should 
routinely be considered, independent of the endpoint/method used for the trial otherwise. This 
is because, if done well, allowing for an interim analysis can substantially reduce the realized 
sample size which is then directly reflected in the expected sample size. The cost for doing so 
is usually a small increase in the maximum sample size. Nevertheless there are a few points 
to consider when considering including interim analyses in a trial.  
Firstly and most importantly, these designs will only result in a benefit if the recruitment is 
slow in comparison to the time it takes to observe the primary endpoint. In situations where 
most or even all patients can be recruited before enough information is collected on the 
primary endpoint, allowing for multiple analyses will not result in any worthwhile benefit 
(except perhaps in terms of time taken). Additionally overrunning, that is having recruited 
patients to the study who are not part of the data that have been used to the decision to stop. 
This reduces the efficiency gain from multi-stage approaches, especially if recruitment is 
quick in comparison to the delay between recruitment and assessment. 
Secondly it is important to ensure that at the time of the first analysis, the totality of the data 
(and not just the information on the primary endpoint) is convincing. It may therefore be 
appropriate to allow stopping for lack of benefit earlier than stopping for efficacy as safety 
data are not mature.  
Thirdly, interim analyses do, besides requiring specific statistical methods, add an additional 
element of complexity to the logistics of a study through additional data cleaning, analysis 
and so on. Moreover, the additional reduction in expected sample size decreases with the 
number of analyses. As a consequence a maximum of two interim analyses is usually 
sufficient for early cancer studies. 
The final point to make is that sequential methods lead to standard maximum likelihood 
estimators of the treatment effect being biased due to the option to stop early (42). Although 
this bias tends to be small, special estimators that overcome these issues have been developed 
(43). 
5. Conclusions 
There are a large number of recent methodological developments that have aimed to improve 
Phase II cancer trials. Many provide an improvement in efficiency over traditional designs 
and analyses used. We believe that several different novel approaches are available that 
should be considered as alternatives to single arm trials using binary endpoints to ensure the 
maximum use of information is made. Additionally we believe that multi-stage designs 
should routinely be considered. Finally it is worth highlighting, that the popularity of single 
armed designs based on response stems from investigating cytotoxic compounds. Newer 
treatments, such as cytostatic agents, are becoming more commonly evaluated through 
comparative trials, possibly using endpoints such as progression-free survival. These designs 
can, however, still be improved further by some of the ideas outlined in this review. Multi-
stage designs, for example, will be efficient in these designs and should be routinely 
considered. 
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Table 1: Characteristics of different designs for early oncology trials. 
   Continuous  
 Binary Categorical Karrison Jaki et al Augmented 
1. Current uptake High Low Moderate Low Low 
      
2. Simplicity      
2a Ease of non-technical 
explanation of method  
High Low High High Moderate 
2b Statistical complexity Low Moderate Low High High 
      
3. Efficiency Low Moderate High High High 
      
4. Number of arms      
4a Single arm Yes No No No  Yes 
4b Comparative 2-arm trial Yes Yes Yes Yes Yes 
      
5. Additional requirements or 









      
 
